|Bid||48.50 x 1100|
|Ask||52.97 x 1000|
|Day's Range||50.83 - 53.13|
|52 Week Range||46.93 - 73.89|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||43.41|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.50|
The Food and Drug Administration has given Israeli drugmaker Teva Pharmaceuticals Inc. final approval to market the first generic naloxone nasal spray to treat opioid overdose, the agency announced Friday. The spray, currently sold under the brand name Narcan by Emergent BioSolutions Inc. subsidiary Adapt Pharma, is a life-saving medication that can stop or reverse the effects of an opioid overdose. Shares of Teva have lost 6.9% so far this year, while the S&P 500 has gained 15.9%. Shares of Emergent BioSolutions have fallen 10.6%. This marks the first time a generic naloxone nasal spray has been approved for use by people without medical training, though generic injectable naloxone products have been available for years. "In the wake of the opioid crisis, a number of efforts are underway to make this emergency overdose reversal treatment more readily available and more accessible. In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone," said Douglas Throckmorton, deputy center director for regulatory programs in the FDA's Center for Drug Evaluation and Research, in a statement. The U.S. in the midst of a deadly opioid epidemic. Almost 400,000 people died from opioid overdose between 1999 and 2017, according to the Centers for Disease Control and Prevention.
GAITHERSBURG, Md., April 18, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the.
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
The interim analysis has shown that with a single dose administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) by Day 7. Further, the immune response was shown to be persistent through the six-month visit, including in the one-dose regimen.
After Emergent BioSolutions Inc.'s (NYSE:EBS) earnings announcement in December 2018, analysts seem extremely confident, with profits predicted to ramp up by an impressive 72% n...
Emergent Biosolutions Inc NYSE:EBSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for EBS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 22. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding EBS are favorable with net inflows of $114.18 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent BioSolutions Inc. (EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule administered intramuscularly in healthy adults. “Emergent is pleased with the advancement of the AV7909 development program,” said Abbey Jenkins, senior vice president and vaccines and anti-infectives business unit head at Emergent BioSolutions. AV7909 is designed to elicit a faster immune response than the currently available anthrax vaccine.
Pennsylvania's life sciences industry honored its own Wednesday night as awards where handed out at Life Sciences Pennsylvania's annual dinner. The event at the Pennsylvania Convention Center drew a record crowd of more than 1,300 people. The awards include two named in honor of biotech pioneer's Hubert J. P. Schoemaker, the co-founder of Centocor, and Frank Baldino Jr., the co-founder of Cephalon.
It hasn't been the best quarter for Emergent BioSolutions Inc. (NYSE:EBS) shareholders, since the share price has fallen 14% in that time. But that doesn't change the fact that theRead More...
Emergent BioSolutions Inc. (EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medical countermeasures that address chemical warfare agents.
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. Emergent BioSolutions Inc had annual average EBITDA growth of 11.30% over the past ten years. Warning! GuruFocus has detected 2 Warning Signs with EBS.
GAITHERSBURG, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Thursday reported a fourth-quarter loss of $3.4 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 7 cents. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 61 cents per share.
GAITHERSBURG, Md., Feb. 21, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS.
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent BioSolutions Inc. (EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent. “The appointment of Seamus to Emergent’s Board comes at a pivotal time in the company’s history, when successive acquisitions have resulted in rapid growth and expansion,” said Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions.